DK0683172T3 - 11,21-bisphenyl-19-norpregnanderivater - Google Patents

11,21-bisphenyl-19-norpregnanderivater

Info

Publication number: DK0683172T3
Authority: DK; Denmark
Prior art keywords: nr5r6; alkyl; bisphenyl; son; optionally substituted
Prior art date: 1994-05-19

Application number

DK95201268.0T

Other languages

English (en)

Inventor

Ronald Gebhard

Hendrikus A A Van Der Voort

Original Assignee

Akzo Nobel Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-05-19

Filing date

1995-05-16

Publication date

1998-03-30

1995-05-16 Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv

1998-03-30 Application granted granted Critical

1998-03-30 Publication of DK0683172T3 publication Critical patent/DK0683172T3/da

Links

125000000217 alkyl group Chemical group 0.000 abstract 4
239000003862 glucocorticoid Substances 0.000 abstract 2
125000005843 halogen group Chemical group 0.000 abstract 2
229910052739 hydrogen Inorganic materials 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
125000003545 alkoxy group Chemical group 0.000 abstract 1
125000002947 alkylene group Chemical group 0.000 abstract 1
125000005530 alkylenedioxy group Chemical group 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
230000001419 dependent effect Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
229910052736 halogen Inorganic materials 0.000 abstract 1
150000002367 halogens Chemical class 0.000 abstract 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
- C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Diabetes (AREA)
Neurology (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Anesthesiology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Steroid Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Seasonings (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

DK95201268.0T 1994-05-19 1995-05-16 11,21-bisphenyl-19-norpregnanderivater DK0683172T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP94201431		1994-05-19

Publications (1)

Publication Number	Publication Date
DK0683172T3 true DK0683172T3 (da)	1998-03-30

Family

ID=8216894

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK95201268.0T DK0683172T3 (da)	1994-05-19	1995-05-16	11,21-bisphenyl-19-norpregnanderivater

Country Status (20)

Country	Link
US (1)	US5620966A (da)
EP (1)	EP0683172B1 (da)
JP (1)	JP3814312B2 (da)
KR (1)	KR100359474B1 (da)
CN (1)	CN1042539C (da)
AT (1)	ATE156836T1 (da)
AU (1)	AU701616B2 (da)
BR (1)	BR9502085A (da)
CA (1)	CA2149496C (da)
DE (1)	DE69500542T2 (da)
DK (1)	DK0683172T3 (da)
ES (1)	ES2106616T3 (da)
FI (1)	FI112491B (da)
GR (1)	GR3025225T3 (da)
HU (1)	HU217429B (da)
NO (1)	NO304379B1 (da)
NZ (1)	NZ272143A (da)
PL (1)	PL180481B1 (da)
RU (1)	RU2152952C2 (da)
ZA (1)	ZA953976B (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL118974A (en) *	1995-08-17	2001-09-13	Akzo Nobel Nv	History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
PL207610B1 (pl)	1999-04-30	2011-01-31	Pfizer Prod Inc	Związki modulujące receptory glukokortykoidowe, ich zastosowanie do wytwarzania leku i środek farmaceutyczny
US7713989B2 (en)	2000-04-27	2010-05-11	Dow Robert L	Glucocorticoid receptor modulators
ES2246292T3 (es)	2000-10-30	2006-02-16	Pfizer Products Inc.	Moduladores de receptor glucocorticoide.
EP1285927A3 (de)	2001-08-16	2005-06-29	Schering Aktiengesellschaft	Verwendung von Glucocorticoid-Rezeptorantagonisten zur Vorbeugung und Behandlung von Erkrankungen des männlichen Reproduktionssystems
US8193172B2 (en)	2001-11-23	2012-06-05	Pop Test Cortisol Llc	Methods for the treatment of major depressive disorder using glucocorticoid receptor antagonists
US7250408B2 (en)	2002-12-16	2007-07-31	Bayer Schering Pharma Ag	Glucocorticoid receptor antagonists for prophylaxis and therapy of glucocorticoid-mediated hypogonadism, of sexual dysfunction and/or infertility
JP4970932B2 (ja) *	2003-03-11	2012-07-11	トロフォ	コレスト−４−エン−３−オンの誘導体の医薬としての使用、これらを含む医薬組成物、新規誘導体及びそれらの製造方法
AU2007287070C1 (en)	2006-08-24	2013-02-14	University Of Tennessee Research Foundation	Substituted acylanilides and methods of use thereof
US10258596B2 (en)	2012-07-13	2019-04-16	Gtx, Inc.	Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10987334B2 (en)	2012-07-13	2021-04-27	University Of Tennessee Research Foundation	Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US12685719B2 (en)	2012-07-13	2026-07-21	University Of Tennessee Research Foundation	Treatment of breast cancer with selective androgen receptor modulators and cyclin-dependent kinase 4/6 inhibitors
US9744149B2 (en)	2012-07-13	2017-08-29	Gtx, Inc.	Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9969683B2 (en)	2012-07-13	2018-05-15	Gtx, Inc.	Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9622992B2 (en)	2012-07-13	2017-04-18	Gtx, Inc.	Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en)	2012-07-13	2019-06-11	Gtx, Inc.	Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
EP3733170A1 (en)	2012-07-13	2020-11-04	Oncternal Therapeutics, Inc.	A method of treating androgen receptor (ar) -positive breast cancers with selective androgen receptor modulator (sarms)
JP6821582B2 (ja)	2015-03-02	2021-01-27	コーセプトセラピューティクス，インコーポレイテッド	Ａｃｔｈ分泌腫瘍を処置するための糖質コルチコイドレセプターアンタゴニストおよびソマトスタチンアナログの使用
JP6754533B2 (ja)	2015-03-30	2020-09-16	コーセプトセラピューティクス，インコーポレイテッド	副腎機能不全を処置するための糖質コルチコイドと組み合わせた糖質コルチコイドレセプターアンタゴニストの使用
MX383318B (es)	2015-08-13	2025-03-13	Corcept Therapeutics Inc	Metodo para diagnosticar de manera diferencial el sindrome de cushing dependiente de la corticotropina.
CN105254697A (zh) *	2015-11-17	2016-01-20	湖南成大生物科技有限公司	△16甾体类化合物的制备方法
JP6765443B2 (ja)	2016-01-19	2020-10-07	コーセプトセラピューティクス，インコーポレイテッド	異所性クッシング症候群の鑑別診断
EP3214092A1 (en) *	2016-03-04	2017-09-06	Bayer Pharma Aktiengesellschaft	Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one
WO2018236749A2 (en)	2017-06-20	2018-12-27	Corcept Therapeutics, Inc.	Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
CN114456223B (zh) *	2022-01-24	2023-07-21	湖南科益新生物医药有限公司	3-缩酮的合成方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1515284A (en) *	1974-05-21	1978-06-21	Gastaud J	Pharmaceutical compositions containing progestogens derived from the 17-alpha-hydroxy-19-nor-progesterone series
FR2528434B1 (fr) *	1982-06-11	1985-07-19	Roussel Uclaf	Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament
ZA8231B (en)	1981-01-09	1982-11-24	Roussel Uclaf	New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2639045B2 (fr) *	1982-03-01	1994-07-29	Roussel Uclaf	Nouveaux produits derives de la structure 3-ceto-delta-4,9-19-nor steroides et leur application comme medicaments
FR2522328B1 (fr) *	1982-03-01	1986-02-14	Roussel Uclaf	Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
DE3461090D1 (en) *	1983-02-18	1986-12-04	Schering Ag	11-beta-aryl-estradienes, process for their preparation and pharmaceutical compositions containing them
FR2549067B1 (fr) *	1983-06-14	1985-12-27	Roussel Uclaf	Derives estradieniques radioactifs marques au tritium, leur procede de preparation et leur application pour l'etude et le dosage radio-immunologique de steroides dans les fluides biologiques
US4780461A (en) *	1983-06-15	1988-10-25	Schering Aktiengesellschaft	13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
DE3347126A1 (de) *	1983-12-22	1985-07-11	Schering AG, 1000 Berlin und 4709 Bergkamen	11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3410880A1 (de) *	1984-03-21	1985-10-03	Schering AG, Berlin und Bergkamen, 1000 Berlin	17-substituierte estradiene und estratriene
DE3506785A1 (de) *	1985-02-22	1986-08-28	Schering AG, Berlin und Bergkamen, 1000 Berlin	11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
US4771042A (en) *	1985-11-25	1988-09-13	The Upjohn Company	Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
FR2598421B1 (fr)	1986-05-06	1988-08-19	Roussel Uclaf	Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
DE3625315A1 (de) *	1986-07-25	1988-01-28	Schering Ag	11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
US4774236A (en) *	1986-09-17	1988-09-27	Research Triangle Institute	17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
ES2053714T3 (es) *	1987-12-12	1994-08-01	Akzo Nv	Proceso para la preparacion de 11-arilesteroides.
JP2785023B2 (ja) *	1987-12-30	1998-08-13	ルセル―ユクラフ	１７α位置を置換された１７β―ＯＨ―１９―ノルステロイドの新誘導体、その製造方法、その薬剤としての使用及びそれを含有する製薬組成物
US4954490A (en) *	1988-06-23	1990-09-04	Research Triangle Institute	11 β-substituted progesterone analogs
DE3822770A1 (de) *	1988-07-01	1990-01-04	Schering Ag	13-alkyl-11ss-phenylgonane
DE3832303A1 (de) *	1988-09-20	1990-04-12	Schering Ag	11ss-phenyl-14ssh-steroide
FR2643638B1 (fr) *	1989-02-24	1991-06-14	Roussel Uclaf	Nouveaux 19-nor steroides ayant en position 11beta une chaine carbonee comportant une fonction amide ou carbamate, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
FR2644789B1 (fr) *	1989-03-22	1995-02-03	Roussel Uclaf	Nouveaux steroides 19-nor, 3-ceto comportant une chaine en 17 aminosubstituee, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
ES2053091T3 (es) *	1989-08-04	1994-07-16	Schering Ag	16alfa,17beta-metilen-estra-4,9-dien-3-onas sustituidas en 11beta.
US5276023A (en) *	1989-08-08	1994-01-04	Roussel Uclaf	19-nor-steroid esters
FR2651435A1 (fr) *	1989-09-07	1991-03-08	Roussel Uclaf	Nouvelle utilisation de composes anti-progestomimetiques.
US5407928A (en) *	1990-08-15	1995-04-18	Schering Aktiengesellschaft	11β-aryl-gona-4,9-dien-3-ones
WO1995004536A1 (en) *	1993-08-04	1995-02-16	Akzo Nobel N.V.	Antiglucocorticoid steroids for the treatment of anxiety disorders

1995
- 1995-05-16 DK DK95201268.0T patent/DK0683172T3/da active
- 1995-05-16 AT AT95201268T patent/ATE156836T1/de not_active IP Right Cessation
- 1995-05-16 CA CA002149496A patent/CA2149496C/en not_active Expired - Fee Related
- 1995-05-16 ES ES95201268T patent/ES2106616T3/es not_active Expired - Lifetime
- 1995-05-16 ZA ZA953976A patent/ZA953976B/xx unknown
- 1995-05-16 EP EP95201268A patent/EP0683172B1/en not_active Expired - Lifetime
- 1995-05-16 DE DE69500542T patent/DE69500542T2/de not_active Expired - Fee Related
- 1995-05-17 NZ NZ272143A patent/NZ272143A/en unknown
- 1995-05-18 AU AU20133/95A patent/AU701616B2/en not_active Ceased
- 1995-05-18 JP JP12005195A patent/JP3814312B2/ja not_active Expired - Fee Related
- 1995-05-18 PL PL95308666A patent/PL180481B1/pl not_active IP Right Cessation
- 1995-05-18 RU RU95107892/04A patent/RU2152952C2/ru not_active IP Right Cessation
- 1995-05-18 HU HU9501461A patent/HU217429B/hu not_active IP Right Cessation
- 1995-05-18 CN CN95105395A patent/CN1042539C/zh not_active Expired - Fee Related
- 1995-05-18 KR KR1019950012374A patent/KR100359474B1/ko not_active Expired - Fee Related
- 1995-05-18 NO NO951968A patent/NO304379B1/no unknown
- 1995-05-18 FI FI952424A patent/FI112491B/fi active
- 1995-05-18 BR BR9502085A patent/BR9502085A/pt not_active IP Right Cessation
- 1995-05-19 US US08/445,119 patent/US5620966A/en not_active Expired - Fee Related
1997
- 1997-10-30 GR GR970402861T patent/GR3025225T3/el unknown

Also Published As

Publication number	Publication date
PL180481B1 (pl)	2001-02-28
FI112491B (fi)	2003-12-15
HU9501461D0 (en)	1995-06-28
DE69500542D1 (de)	1997-09-18
ZA953976B (en)	1996-01-19
BR9502085A (pt)	1996-03-05
PL308666A1 (en)	1995-11-27
NO304379B1 (no)	1998-12-07
AU701616B2 (en)	1999-02-04
NO951968D0 (no)	1995-05-18
HUT71804A (en)	1996-02-28
US5620966A (en)	1997-04-15
EP0683172B1 (en)	1997-08-13
NO951968L (no)	1995-11-20
ATE156836T1 (de)	1997-08-15
NZ272143A (en)	1995-11-27
HU217429B (hu)	2000-01-28
RU2152952C2 (ru)	2000-07-20
DE69500542T2 (de)	1998-01-02
CN1126727A (zh)	1996-07-17
JP3814312B2 (ja)	2006-08-30
CA2149496C (en)	2006-12-19
CA2149496A1 (en)	1995-11-20
CN1042539C (zh)	1999-03-17
FI952424L (fi)	1995-11-20
EP0683172A1 (en)	1995-11-22
KR100359474B1 (ko)	2003-03-12
GR3025225T3 (en)	1998-02-27
FI952424A0 (fi)	1995-05-18
JPH07316187A (ja)	1995-12-05
AU2013395A (en)	1995-11-30
RU95107892A (ru)	1997-02-10
ES2106616T3 (es)	1997-11-01
KR950032267A (ko)	1995-12-20

Publication	Publication Date	Title
FI952424A0 (fi)	1995-05-18	11,21-bisfenyyli-19-norpregaanijohdannaisia
DK0590919T3 (da)	2000-04-17	Terapeutiske midler mod Parkinsons sygdom
IL158459A0 (en)	2004-05-12	Quinoline derivatives and quinazoline derivatives having azolyl group
TW427887B (en)	2001-04-01	Pharmaceutical composition comprising a benzimidazole derivative for treating viral infections
GB9211172D0 (en)	1992-07-08	Compounds
MX9701685A (es)	1997-06-28	Nuevos derivados de bencimidazol que tienen la actividad de inhibicion de la fosfodiestearasa cgmp.
DK0390654T3 (da)	1995-04-03	Aminobenzensulfonsyrederivater
PT770079E (pt)	2003-06-30	Derivados heterobiciclicos
PT918776E (pt)	2004-07-30	Sintese total de acilfulvenos antitumorais
DE69312567D1 (de)	1997-09-04	2-Formylpyridin-Thiosemicarbazonderivate, ihre Herstellung und ihre Verwendung als Antitumor Mittel
ATE223411T1 (de)	2002-09-15	1-methylcarbapenem-derivate
CA2014521A1 (en)	1990-10-15	2-Substituted N,N'-Ditrimethoxybenzoyl Piperazines, a Preparation Process of the Same and Therapeutic Compositions Containing Them
EP0785190A3 (da)	1997-08-27
DE60000978D1 (de)	2003-01-23	22r-hydroxycholesta-8,14-diene derivate zur hemmung der meiose
ATE122892T1 (de)	1995-06-15	Zusammensetzung gegen katarakt.
TW275629B (da)	1996-05-11
BR0108448A (pt)	2003-04-01	Derivados de tetraidrofuril óxi-e amino-substituìdos com atividade antitumor